MA37670B1 - Anticorps anti-transglutaminase 2 - Google Patents
Anticorps anti-transglutaminase 2Info
- Publication number
- MA37670B1 MA37670B1 MA37670A MA37670A MA37670B1 MA 37670 B1 MA37670 B1 MA 37670B1 MA 37670 A MA37670 A MA 37670A MA 37670 A MA37670 A MA 37670A MA 37670 B1 MA37670 B1 MA 37670B1
- Authority
- MA
- Morocco
- Prior art keywords
- central region
- transglutaminase
- relates
- antibodies
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
L'invention concerne des anticorps et des fragments de liaison à l'antigène de ceux-ci, qui se lient sélectivement à un épitope dans la région centrale de la transglutaminase de type 2 (tg2). De nouveaux épitopes dans la région centrale de tg2 sont décrits. L'invention concerne des anticorps inhibant la tg2 humaine et leurs utilisations, notamment en médecine, par exemple pour le traitement et/ou le diagnostic de troubles tels que la maladie cœliaque, la formation de cicatrices, les maladies liées à la fibrose, les maladies neurodégénératives/neurologiques et le cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1209096.5A GB201209096D0 (en) | 2012-05-24 | 2012-05-24 | Compounds |
| PCT/GB2013/051373 WO2013175229A1 (fr) | 2012-05-24 | 2013-05-24 | Anticorps anti-transglutaminase 2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37670A1 MA37670A1 (fr) | 2016-05-31 |
| MA37670B1 true MA37670B1 (fr) | 2019-12-31 |
Family
ID=46546551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37670A MA37670B1 (fr) | 2012-05-24 | 2013-05-24 | Anticorps anti-transglutaminase 2 |
Country Status (39)
| Country | Link |
|---|---|
| US (3) | US10005846B2 (fr) |
| EP (2) | EP2855530B1 (fr) |
| JP (2) | JP6411998B2 (fr) |
| KR (1) | KR102091223B1 (fr) |
| CN (1) | CN104321346B (fr) |
| AU (1) | AU2013265025B2 (fr) |
| BR (1) | BR112014029089B1 (fr) |
| CA (1) | CA2874488C (fr) |
| CL (1) | CL2014003125A1 (fr) |
| CO (1) | CO7151528A2 (fr) |
| CY (2) | CY1121932T1 (fr) |
| DK (2) | DK2855530T3 (fr) |
| EA (1) | EA036810B1 (fr) |
| EC (1) | ECSP14030942A (fr) |
| ES (2) | ES2728856T3 (fr) |
| GB (1) | GB201209096D0 (fr) |
| HK (1) | HK1203974A1 (fr) |
| HR (2) | HRP20191293T1 (fr) |
| HU (2) | HUE045539T2 (fr) |
| IL (1) | IL235369B (fr) |
| IN (1) | IN2014MN02231A (fr) |
| LT (2) | LT3521315T (fr) |
| MA (1) | MA37670B1 (fr) |
| ME (1) | ME03393B (fr) |
| MX (1) | MX367517B (fr) |
| MY (1) | MY185966A (fr) |
| NZ (1) | NZ701424A (fr) |
| PE (1) | PE20150346A1 (fr) |
| PH (1) | PH12014502582B1 (fr) |
| PL (2) | PL3521315T3 (fr) |
| PT (2) | PT3521315T (fr) |
| RS (2) | RS61286B1 (fr) |
| SG (1) | SG11201407053YA (fr) |
| SI (2) | SI3521315T1 (fr) |
| TN (1) | TN2014000458A1 (fr) |
| TR (1) | TR201906781T4 (fr) |
| UA (1) | UA117657C2 (fr) |
| WO (1) | WO2013175229A1 (fr) |
| ZA (1) | ZA201408213B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110055235A (zh) * | 2019-05-14 | 2019-07-26 | 深圳市亚辉龙生物科技股份有限公司 | 用于转谷氨酰胺酶抗体检测的抗原及其制备方法、试剂盒及检测方法 |
| GB202115127D0 (en) | 2021-10-21 | 2021-12-08 | Ucb Biopharma Sprl | Formulations |
| GB202115121D0 (en) | 2021-10-21 | 2021-12-08 | Ucb Biopharma Sprl | Formulations |
| TW202334240A (zh) | 2021-11-18 | 2023-09-01 | 比利時商Ｕｃｂ生物製藥公司 | 治療進行性慢性間質性肺部疾病之方法 |
| GB202116665D0 (en) | 2021-11-18 | 2022-01-05 | UCB Biopharma SRL | Method for the treatment of a scleroderma disease |
| GB202118010D0 (en) | 2021-12-13 | 2022-01-26 | UCB Biopharma SRL | Method for detecting and/or quantifying crosslinks formed by transglutaminases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4912120A (en) | 1986-03-14 | 1990-03-27 | Syntex (U.S.A.) Inc. | 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors |
| AU1268192A (en) | 1991-01-04 | 1992-08-17 | Board Of Regents, The University Of Texas System | Cloning and expression of tissue transglutaminases |
| WO1998004245A1 (fr) | 1996-07-25 | 1998-02-05 | The Victoria University Of Manchester | Utilisation de modulateurs de la transglutaminase pour favoriser la cicatrisation |
| GB0103024D0 (en) * | 2001-02-07 | 2001-03-21 | Rsr Ltd | Assay for Autoantibodies to tissue transglutaminase |
| CA2514942A1 (fr) | 2003-02-02 | 2004-08-19 | Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services | Methodes et compositions de traitement de la maladie de parkinson et d'autres a-synucleinopathies |
| GB0314262D0 (en) | 2003-06-19 | 2003-07-23 | Univ Nottingham Trent | Novel compounds and methods of using the same |
| WO2006100679A2 (fr) * | 2005-03-22 | 2006-09-28 | Quark Pharmaceuticals, Inc. | Anticorps de recombinaison diriges contre la transglutaminase humaine de type ii et utilisations de ces anticorps |
| WO2008063760A2 (fr) | 2006-10-18 | 2008-05-29 | The University Of Texas M.D. Anderson Cancer Center | Méthodes de traitement de cancer ciblant la transglutaminase |
| US8614296B2 (en) * | 2008-04-24 | 2013-12-24 | Gene Techno Science Co., Ltd. | Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof |
| EP2408471B1 (fr) | 2009-03-19 | 2015-06-24 | Queensland University Of Technology | Cibles pour la signalisation des facteurs de croissance et procédés thérapeutiques |
| HU0900195D0 (en) * | 2009-04-01 | 2009-06-29 | Debreceni Egyetem | Diagnosis and treatment of gluten-induced autoimmune diseases |
| HU0900199D0 (en) * | 2009-04-01 | 2009-06-29 | Debreceni Egyetem | Diagnosis of gluten-induced autoimmune diseases |
| EP2579861A2 (fr) | 2010-06-02 | 2013-04-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibiteurs de la transglutaminase 2 destinés être utilisés dans la prévention ou le traitement de la glomérulonéphrite maligne |
| GB2490655A (en) | 2011-04-28 | 2012-11-14 | Univ Aston | Modulators of tissue transglutaminase |
-
2012
- 2012-05-24 GB GBGB1209096.5A patent/GB201209096D0/en not_active Ceased
-
2013
- 2013-05-24 SI SI201331811T patent/SI3521315T1/sl unknown
- 2013-05-24 TR TR2019/06781T patent/TR201906781T4/tr unknown
- 2013-05-24 MX MX2014014264A patent/MX367517B/es active IP Right Grant
- 2013-05-24 LT LTEP19163818.8T patent/LT3521315T/lt unknown
- 2013-05-24 DK DK13730049.7T patent/DK2855530T3/da active
- 2013-05-24 MY MYPI2014003271A patent/MY185966A/en unknown
- 2013-05-24 US US14/402,675 patent/US10005846B2/en active Active
- 2013-05-24 SI SI201331487T patent/SI2855530T1/sl unknown
- 2013-05-24 EA EA201492162A patent/EA036810B1/ru not_active IP Right Cessation
- 2013-05-24 HU HUE13730049A patent/HUE045539T2/hu unknown
- 2013-05-24 AU AU2013265025A patent/AU2013265025B2/en active Active
- 2013-05-24 ES ES13730049T patent/ES2728856T3/es active Active
- 2013-05-24 ME MEP-2019-181A patent/ME03393B/fr unknown
- 2013-05-24 MA MA37670A patent/MA37670B1/fr unknown
- 2013-05-24 IN IN2231MUN2014 patent/IN2014MN02231A/en unknown
- 2013-05-24 CA CA2874488A patent/CA2874488C/fr active Active
- 2013-05-24 PL PL19163818T patent/PL3521315T3/pl unknown
- 2013-05-24 KR KR1020147036419A patent/KR102091223B1/ko active IP Right Grant
- 2013-05-24 SG SG11201407053YA patent/SG11201407053YA/en unknown
- 2013-05-24 PT PT191638188T patent/PT3521315T/pt unknown
- 2013-05-24 RS RS20210033A patent/RS61286B1/sr unknown
- 2013-05-24 DK DK19163818.8T patent/DK3521315T3/da active
- 2013-05-24 LT LTEP13730049.7T patent/LT2855530T/lt unknown
- 2013-05-24 CN CN201380026672.3A patent/CN104321346B/zh active Active
- 2013-05-24 PT PT13730049T patent/PT2855530T/pt unknown
- 2013-05-24 HU HUE19163818A patent/HUE052490T2/hu unknown
- 2013-05-24 UA UAA201413832A patent/UA117657C2/uk unknown
- 2013-05-24 RS RS20190909A patent/RS59135B1/sr unknown
- 2013-05-24 EP EP13730049.7A patent/EP2855530B1/fr active Active
- 2013-05-24 PL PL13730049T patent/PL2855530T3/pl unknown
- 2013-05-24 EP EP19163818.8A patent/EP3521315B1/fr active Active
- 2013-05-24 BR BR112014029089-0A patent/BR112014029089B1/pt active IP Right Grant
- 2013-05-24 WO PCT/GB2013/051373 patent/WO2013175229A1/fr active Application Filing
- 2013-05-24 JP JP2015513275A patent/JP6411998B2/ja active Active
- 2013-05-24 PE PE2014002040A patent/PE20150346A1/es active IP Right Grant
- 2013-05-24 ES ES19163818T patent/ES2835383T3/es active Active
- 2013-05-24 NZ NZ701424A patent/NZ701424A/en unknown
-
2014
- 2014-10-28 TN TN2014000458A patent/TN2014000458A1/fr unknown
- 2014-10-28 IL IL235369A patent/IL235369B/en active IP Right Grant
- 2014-11-10 ZA ZA2014/08213A patent/ZA201408213B/en unknown
- 2014-11-18 CL CL2014003125A patent/CL2014003125A1/es unknown
- 2014-11-19 PH PH12014502582A patent/PH12014502582B1/en unknown
- 2014-12-12 EC ECIEPI201430942A patent/ECSP14030942A/es unknown
- 2014-12-23 CO CO14281628A patent/CO7151528A2/es unknown
-
2015
- 2015-05-11 HK HK15104401.8A patent/HK1203974A1/xx unknown
-
2018
- 2018-05-23 US US15/987,611 patent/US10961319B2/en active Active
- 2018-05-30 JP JP2018104139A patent/JP2018166510A/ja active Pending
-
2019
- 2019-07-18 HR HRP20191293TT patent/HRP20191293T1/hr unknown
- 2019-07-29 CY CY20191100807T patent/CY1121932T1/el unknown
-
2020
- 2020-12-14 US US17/121,541 patent/US11718686B2/en active Active
- 2020-12-23 HR HRP20202059TT patent/HRP20202059T1/hr unknown
-
2021
- 2021-01-11 CY CY20211100013T patent/CY1123926T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA37670B1 (fr) | Anticorps anti-transglutaminase 2 | |
| Doppler et al. | Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy | |
| MA44312A (fr) | Anticorps et leurs méthodes d'utilisation | |
| MA47313A (fr) | Formulations sous-cutanées d'anticorps her2 | |
| MA40041A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
| EP2987807A3 (fr) | Anticorps dirigés contre tau phosphorylée | |
| MA38194B1 (fr) | Anticorps anti-ceacam5 et leurs utilisations | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| MA31899B1 (fr) | Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant | |
| MA30337B1 (fr) | Anticorps | |
| UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
| UA116614C2 (uk) | Антитіло до фактора d і його застосування | |
| MX356800B (es) | Anticuerpo tau humanizado. | |
| MX2021011715A (es) | Anticuerpos contra amiloide-? con piroglutamato y usos de estos campo de la invención. | |
| MA34175B1 (fr) | Anticorps anti-cxcr4 humanisés pour le traitement de cancer | |
| BRPI0708101B8 (pt) | anticorpo, ou seu fragmento de ligação a antígeno, que especificamente se liga a il-22, composição farmacêutica, ácido nucléico isolado, vetor de expressão, célula hospedeira, método de produção do mesmo e kit diagnóstico | |
| MA38161A1 (fr) | Anticorps anti-bmp-6 | |
| US20220402979A1 (en) | Biomarkers and treatments of alzheimer's disease and mild cognitive impairment | |
| Hofstad et al. | Early supported discharge after stroke in Bergen (ESD Stroke Bergen): three and six months results of a randomised controlled trial comparing two early supported discharge schemes with treatment as usual | |
| MA44917A1 (fr) | Anticorps ou son fragment de liaison d’antigènes apte a se lier au récepteur d'interleukine-6 de l'humain. | |
| MA47976B1 (fr) | Anticorps dirigés contre trem2 et leur utilisation | |
| BR112022012010A2 (pt) | Anticorpos, ácido nucleico isolado, célula hospedeira, formulação farmacêutica, uso do anticorpo, método de produção de um anticorpo, método de tratamento de um indivíduo que tem câncer e método de tratamento de um indivíduo que tem uma doença inflamatória ou autoimune | |
| MA35580B1 (fr) | Composition pharmaceutique | |
| Ouyang et al. | Galectin-1 serum levels reflect tumor burden and adverse clinical features in Hodgkin lymphoma | |
| FR3008099B1 (fr) | Peptides immunogenes de l'antigene tumoral cycline b1 |